As of Apr 17
| -0.01 / -0.50%|
The 1 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a 0.00% increase from the last price of 2.00.
The current consensus among 1 polled investment analysts is to Hold stock in Protalix Biotherapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.